TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mean urinary frequency of \>=8 micturitions per 24 hours as verified by the screening bladder diary prior to Start of Placebo run in visit (Visit 2)~* Mean number of micturition related urgency episodes \>=3 per 24 hours as verified by the screening bladder diary prior to Start of Placebo run in /Visit 2 (Urgency episodes are defined as those with Urinary Sensation Scale rating \>=3)~* Mean number of micturition related nocturnal urgency episodes \>=2 but no more than 8 episodes per 24 hours as verified by the bladder diary at Visit 2 (nocturnal urgency episodes are defined as those with Urinary Sensation Scale rating of \>3 recorded in the bed time section of the bladder diary)~Exclusion Criteria:~* A known recent history or previous diagnosis of any sleep disorder such as obstructive sleep apnea, primary insomnia, periodic limb movement, parasomnia~* Nocturia due to other underlying uncontrolled conditions, such as congestive heart failure, diabetes mellitus, diabetes insipidus, polyuria of any cause, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults~* Male or female~* Must meet Attention-Deficit/Hyperactivity Disorder (ADHD) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision™ (DSM-IV-TR™) criteria~Exclusion Criteria:~* Comorbidity with major psychiatric disorder~* Clinically significant depression or anxiety~* Patients with significant medical conditions~* Current alcohol/drugs abuse/dependence~* Concomitant excluded medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* confirmed second-stage T.b. gambiense infection : presence of the parasite in blood, lymph node fluid or CSF and \>20 white blood cells/µL in CSF. In presence of blood in the CSF, lumbar puncture must be done again or the patient cannot be included in the study (see 10.9.1).~* and of age 15 years or older.~* and resident in __________ (each site will define boundaries or maximum distance)~* and written informed consent of the patient or of a legally acceptable representative if the patient is a minor (\<18 years for both genders in Uganda and Angola, \<18 years for males and \<16 years for females in the Democratic Republic of Congo) or unable to communicate.~Exclusion Criteria:~* pregnant woman (systematic testing of women of childbearing potential)~* treated for late-stage HAT during the last 36 months. Patients previously treated for first-stage (pentamidine) can be included.~* unlikely to have access to the treatment centre or be accessible at their place of residence for 18 months after treatment~* unable to take oral medication~* suffering from conditions other than second stage HAT that seriously limit the chances of survival over 18 months time~* Severe anemia (Hb\< 5g/dl)~* Severe underlying diseases upon admission (e.g. Active tuberculosis and/or being treated for TB; Bacterial or cryptococcal meningitis; Stages 3 or 4 HIV/AIDS according to the WHO clinical definition) (WHO, 1986).~* Severe renal failure based on clinical examination combined with biochemistry if available: creatinine clearance \<20mL/min~* Severe hepatic failure based on clinical examination combined with biochemistry if available: total bilirubin \>50 µmol/L, ALAT/GPT \>70 UI/L, unless these laboratory values are determined by the investigator as likely due to conditions other than hepatic failure.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia or schizoaffective disorder and nicotine dependence~* Fagerstrom Test for Nicotine Dependence (FTND) score greater than 5~* Smokes at least 20 cigarettes per day (1 pack per day)~* Expired breath CO level \> 10 ppm and cotinine level \> 210 ng/ml at the baseline measurement~* Currently taking a stable dose of antipsychotic~* Complete remission from positive symptoms of psychosis as judged by a psychiatric evaluation~Exclusion Criteria:~* Meets criteria for current abuse or dependence for any alcohol or illicit substance within the past month~* History of hypersensitivity to bupropion or the nicotine transdermal patch (NTP)~* Current diagnosis of a serious documented medical disorder that would make bupropion treatment risky OR results of psychiatric/medical screening that suggest a reason for concern (e.g., a history of severe heart, liver, or kidney disease or diabetes mellitus)~* Currently taking monoamine oxidase inhibitors or bupropion (Zyban or Wellbutrin)~* Currently taking diabetes mellitus medications, St. John's Wort, appetite suppressants, ephedrine-containing medications, theophylline, clonidine, reserpine, methyldopa, or anti-anginal medications (e.g., beta-blockers, calcium channel blockers, nitroglycerin preparations)~* History of schizoaffective disorder and not stabilized on a mood stabilizer (e.g., lithium, valproate, carbamazepine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Nicotine Patch + Bupropion
- 2 (Type: PLACEBO_COMPARATOR): Nicotine patch + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants greater than or equal to 36 weeks EGA~* Intrauterine opioid exposure~* Primary diagnosis of NAS~* Parental permission to participate~Exclusion Criteria:~* Infants less than 36 weeks EGA~* Major congenital anomalies~* Latrogenic drug withdrawal~* Diagnosis of infection or respiratory distress~* Prior initiation of opioid replacement therapy~* Non-English speaking~* Infants with respiratory conditions

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Weeks
- Healthy Volunteers: f

Study Arms:
- Standard therapy plus Aromatherapy (Type: EXPERIMENTAL): These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
- Standard therapy ALONE (Type: NO_INTERVENTION): These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age: 30 years or older.~2. Diagnosis: confirmed open-angle glaucoma in at least one eye:~   1. glaucomatous visual field loss on Humphrey 24-2 or 10-2 perimetry~  2. glaucomatous optic disc cupping~  3. agreement between two baseline exams for reliability~3. Best corrected visual acuity at least 20/60 in at least one eye.~4. Prior Humphrey visual fields demonstrate acceptable reliability standards.~Exclusion Criteria:~1. Extensive Humphrey visual field damage consisting of either a mean deviation (MD) \< -15 decibels or a clinically determined threat to fixation in both hemifields.~2. Evidence of exfoliation or pigment dispersion.~3. History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy.~4. History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis).~5. History or signs of intraocular trauma.~6. Severe or potentially progressive retinal disease such as retinal degeneration, diabetic retinopathy, and retinal detachment.~7. Any abnormality preventing reliable applanation tonometry.~8. Current use of any ophthalmic or systemic steroid which may interfere with this investigation.~9. Cataract surgery within the past year.~10. Resting pulse \< 50 beats per minute.~11. Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glaucoma patients (Type: None): Patients with Glaucoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Rectocele~* Intussusception~Exclusion Criteria:~* Non operability~* inflammatory bowel disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stapled transanal rectum resection (Type: OTHER): patients operated with stapled transanal rectum resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Couples Health Project: Couples-based Intervention to Reduce Drug Use and HIV Transmission Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least one member of the couple must be 18 to 29 years of age~* Both members assigned male gender at birth and currently identify as male~* At least one member of the couple reports an HIV-negative serostatus~* Couple has been together for at least 3 months~* The use of at least one of the following substances in the past 30 days (only one partner): marijuana, cocaine/crack, amphetamines, ecstasy, GHB, ketamine, nitrates, prescriptionn drug misuse~* At least one member of the couple, in the past 30 days, had condomless anal sex (CAS) with a casual partner and/or CAS with a non-monogamous or serodiscordant main partner.~* Both members must be able to communicate in English~* Both members must reside in the NYC metro area~Exclusion Criteria:~* Either member of the couple reports IPV, which is defined as serious physical or sexual violence that occurs outside the context of consensual bondage or sado-masochistic sexual play, which results in concerns of safety.~* Inconsistencies between information provided in the eligibility screener and the in-person meeting or any issues that might hinder participation. The couple may also be deemed ineligible if participant responses are sufficiently inconsistent to call into question the validity of their individual responses~* The couple reports a sero-concordant HIV-positive serostatus~* Unstable, serious psychiatric symptoms (assessed at Baseline)~* Currently suicidal/homicidal~* Evidence of gross cognitive impairment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Couples Health Project (CHP) (Type: EXPERIMENTAL): The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
- Education (Type: ACTIVE_COMPARATOR): The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion:~* healthy adult males~Exclusion:~* past or current psychiatric or neurological disorder~* head trauma~* substance abuse~* medication~* fMRI contraindications (e.g. metal implants)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- High anxiety group (single dose) (Type: EXPERIMENTAL): Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
- High anxiety group (3 doses) (Type: EXPERIMENTAL): Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
- High anxiety group (5 doses) (Type: EXPERIMENTAL): Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
- Low anxiety group (single dose) (Type: EXPERIMENTAL): Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
- Low anxiety group (3 doses) (Type: EXPERIMENTAL): Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
- Low anxiety group (5 doses) (Type: EXPERIMENTAL): Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Has chronic HCV genotype 1 infection~* Is treatment-experienced~* For the non-cirrhotic population, has had a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma; for the cirrhotic population, has had a liver biopsy with evidence of cirrhosis and without evidence of hepatocellular carcinoma.~Exclusion criteria:~* Has not tolerated previous course peg-IFN and RBV~* Is unlikely to tolerate at least 24 weeks of continuous therapy with Peg-IFN and RBV~* Is co-infected with Human Immunodeficiency Virus (HIV) and/or hepatitis B~* Consumes excessive amounts of alcohol~* Has a history of drug or alcohol abuse~* If female, participant is pregnant or breastfeeding~* Has been in a clinical trail with an investigational drug in the last 30 days~* Has used IFN/Peg-IFN and RBV in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 24-wk Vaniprevir 600 mg + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
- 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
- 48-wk Vaniprevir 300 mg + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 300 mg (total daily dose, taken once daily \[q.d.\]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
- 48-wk Vaniprevir 600 mg + Peg-IFN/RBV (Type: EXPERIMENTAL): Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
- 48-wk PBO + Peg-IFN/RBV (Type: PLACEBO_COMPARATOR): PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age from 60 days to 90 days;~* Adults, parent(s) or guardians are able to understand and sign informed consent for participation;~* Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;~* Infants no vaccinated with poliovaccine or other preventive biologicals in recent 7 days;~* Axillary temperature ≤37℃.~Exclusion Criteria:~* Have medical record of participants or their family on allergy, convulsion, falling sickness, encephalopathy and psychopathy;~* Low platelet or bleeding disorder do not allow vaccination into the muscle;~* Have damaged or lower immunological function;~* Received blood, plasma or immunoglobulin treatment since birth;~* Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );~* Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.~Exclusion Criteria for doses 2 and 3~* Have serious anaphylaxis or high fever, convulsion during first dose;~* Have any circus of Exclusion Criteria after Eligible for study;~* Have serious adverse event which related to previous vaccination; Withdrawal and Discontinuance Criteria;~* Received necessary or interference study drugs such as: immune-inhibition or immune-stimulating agents;~* Vaccinated with any other vaccine（except DTP）;~* Stop observation determined by investigator owing to occurring serious adverse event;

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- Cohort 1: Experiment Infants (Type: EXPERIMENTAL): Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
- Cohort 2: Experiment infants (Type: EXPERIMENTAL): Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
- Cohort 3: Experiment infants (Type: EXPERIMENTAL): Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
- Cohort 4: Experiment infants (Type: EXPERIMENTAL): Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
- Cohort 5: Experiment infants (Type: EXPERIMENTAL): Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete